Advertisement

Risks and Side Effects of Medical Therapy

  • Tracey E. Peterson
  • Corey A. SiegelEmail author
Chapter

Abstract

The risks of treatment for inflammatory bowel disease (IBD) are of concern for both patients and providers. Overall, IBD treatments are safe, but there are a range of important potential side effects that need to be discussed with patients. This chapter will review the risks associated with aminosalicylates, corticosteroids, immunomodulators, biologics, and the newer small molecules. In addition to discussing these possible adverse events, guidance is offered on the best methods for communicating these risks to patients.

Keywords

Risk Lymphoma Infection 

References

  1. Arnason BGW, Jacobs G, Hanlon M, Clay BH, Noronha ABC, Auty A, Davis B, Nath A, Bouchard JP, Belanger C, Gosselin F (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53:457–465CrossRefGoogle Scholar
  2. Baecklund E, Askling J, Rosenquist R et al (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254–261CrossRefGoogle Scholar
  3. Beaugerie L, Brousse N, Bouvier AM et al (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374:1617–1625CrossRefGoogle Scholar
  4. Buchbinder R, Barber M, Heuzenroeder L et al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 59:794–799CrossRefGoogle Scholar
  5. Chung ES, Packer M, Lo KH et al (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133–3140CrossRefGoogle Scholar
  6. Colombel JF, Sandborn WJ, Reinisch W et al (2010) Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362:1383–1395CrossRefGoogle Scholar
  7. Colombel JF, Sands BE, Rutgeerts P et al (2017) The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 66:839–851CrossRefGoogle Scholar
  8. Curkovic I, Egbring M, Kullak-Ublick GA (2013) Risks of inflammatory bowel disease treatment with glucocorticosteroids and aminosalicylates. Dig Dis 31:368–373CrossRefGoogle Scholar
  9. Danese S, Siegel CA, Peyrin-Biroulet L (2014) Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 39:1095–1103CrossRefGoogle Scholar
  10. Dayharsh GA, Loftus EV Jr, Sandborn WJ et al (2002) Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122:72–77CrossRefGoogle Scholar
  11. de Jong DJ, Tielen J, Habraken CM et al (2005) 5-Aminosalicylates and effects on renal function in patients with Crohn’s disease. Inflamm Bowel Dis 11:972–976CrossRefGoogle Scholar
  12. Dulai PS, Singh S, Jiang X et al (2016) The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol 111:1147–1155CrossRefGoogle Scholar
  13. Ejima-Yamada K, Oshiro Y, Okamura S et al (2017) Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders. Virchows Arch 470:205–215CrossRefGoogle Scholar
  14. Farrell RJ, Ang Y, Kileen P et al (2000) Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47:514–519CrossRefGoogle Scholar
  15. Feagan BG, McDonald JW, Panaccione R et al (2013) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology 146(3):681–688CrossRefGoogle Scholar
  16. Feagan BG, Sandborn WJ, Gasink C et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375:1946–1960CrossRefGoogle Scholar
  17. Kotlyar DS, Osterman MT, Diamond RH et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 9:36–41 e1CrossRefGoogle Scholar
  18. Lim WC, Wang Y, MacDonald JK et al (2016) Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev 7:CD008870PubMedGoogle Scholar
  19. Loftus EV Jr, Kane SV, Bjorkman D (2004) Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19:179–189CrossRefGoogle Scholar
  20. Long MD, Martin CF, Pipkin CA et al (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143:390–399 e1CrossRefGoogle Scholar
  21. Magro F, Peyrin-Biroulet L, Sokol H et al (2014) Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis 8:31–44CrossRefGoogle Scholar
  22. Mason M, Siegel CA (2013) Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 19:1306–1321CrossRefGoogle Scholar
  23. Meng Y, Dongmei L, Yanbin P et al (2014) Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol 39:696–707CrossRefGoogle Scholar
  24. Osterman MT, Sandborn WJ, Colombel JF et al (2014) Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology 146:941–949CrossRefGoogle Scholar
  25. Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al (2011) Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 141:1621–28 e1-5CrossRefGoogle Scholar
  26. Present DH (2000) How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48–57; discussion 58CrossRefGoogle Scholar
  27. Ransford RA, Langman MJ (2002) Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51:536–539CrossRefGoogle Scholar
  28. Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 15:1515–1525CrossRefGoogle Scholar
  29. Rutgeerts P, Lofberg R, Malchow H et al (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331:842–845CrossRefGoogle Scholar
  30. Sandborn WJ, Su C, Sands BE et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736CrossRefGoogle Scholar
  31. Sands BE (2017) Leukocyte anti-trafficking strategies: current status and future directions. Dig Dis 35:13–20CrossRefGoogle Scholar
  32. Siegel CA (2010) Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 16:2168–2172CrossRefGoogle Scholar
  33. Siegel CA, Sands BE (2005) Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 22:1–16CrossRefGoogle Scholar
  34. Siegel CA, Levy LC, Mackenzie TA et al (2008) Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 14:1–6CrossRefGoogle Scholar
  35. Siegel CA, Marden SM, Persing SM et al (2009) Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol 7:874–881CrossRefGoogle Scholar
  36. Toruner M, Loftus EV Jr, Harmsen WS et al (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134:929–936CrossRefGoogle Scholar
  37. Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 353:362–368CrossRefGoogle Scholar
  38. Vos AC, Bakkal N, Minnee RC et al (2011) Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 17:1837–1845CrossRefGoogle Scholar
  39. Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical CenterLebanonUSA

Personalised recommendations